Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials
Authors
Keywords
-
Journal
Translational Neurodegeneration
Volume 10, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-26
DOI
10.1186/s40035-021-00257-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The clinical trial landscape in amyotrophic lateral sclerosis—Past, present, and future
- (2020) Heike J. Wobst et al. MEDICINAL RESEARCH REVIEWS
- Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS
- (2020) Namita A. Goyal et al. MUSCLE & NERVE
- Serum neurofilament light levels in normal aging and their association with morphologic brain changes
- (2020) Michael Khalil et al. Nature Communications
- Confounding effect of blood volume and body mass index on blood neurofilament light chain levels
- (2020) Ali Manouchehrinia et al. Annals of Clinical and Translational Neurology
- Validation of serum neurofilaments as prognostic and potential pharmacodynamic biomarkers for ALS
- (2020) Michael Benatar et al. NEUROLOGY
- Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis
- (2020) Johannes Dorst et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Renal function is associated with blood neurofilament light chain level in older adults
- (2020) Shoshin Akamine et al. Scientific Reports
- Refining eligibility criteria for amyotrophic lateral sclerosis clinical trials
- (2019) Ruben P.A. van Eijk et al. NEUROLOGY
- Diagnostic and Prognostic Performance of Neurofilaments in ALS
- (2019) Koen Poesen et al. Frontiers in Neurology
- A ferroptosis–based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis
- (2019) David Devos et al. Scientific Reports
- Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials
- (2019) Leonard H. van den Berg et al. NEUROLOGY
- ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis
- (2019) Paul Lingor et al. Frontiers in Neurology
- Masitinib as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomized clinical trial
- (2019) Jesus S. Mora et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Serum neurofilament light chain at time of diagnosis is an independent prognostic factor of survival in amyotrophic lateral sclerosis
- (2019) E. Thouvenot et al. EUROPEAN JOURNAL OF NEUROLOGY
- Neurochemical biomarkers in amyotrophic lateral sclerosis
- (2019) Federico Verde et al. CURRENT OPINION IN NEUROLOGY
- Effect of High‐Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis
- (2019) Albert C. Ludolph et al. ANNALS OF NEUROLOGY
- Development and Validation of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS)
- (2019) Christina N. Fournier et al. JAMA Neurology
- Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial
- (2018) Albert C Ludolph et al. LANCET NEUROLOGY
- Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort
- (2018) Nimish J. Thakore et al. MUSCLE & NERVE
- Serum neurofilament light chain levels as a marker of upper motor neuron degeneration in patients with Amyotrophic Lateral Sclerosis
- (2018) B. Gille et al. NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Neurofilament light chain in serum for the diagnosis of amyotrophic lateral sclerosis
- (2018) Federico Verde et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
- (2017) Koji Abe et al. LANCET NEUROLOGY
- How much do clinical trials cost?
- (2017) Linda Martin et al. NATURE REVIEWS DRUG DISCOVERY
- Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis
- (2017) Emily Feneberg et al. NEUROLOGY
- Shortcomings in the Current Amyotrophic Lateral Sclerosis Trials and Potential Solutions for Improvement
- (2017) Nakul Katyal et al. Frontiers in Neurology
- Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net
- (2016) Petra Steinacker et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Predicting disease progression in amyotrophic lateral sclerosis
- (2016) Albert A. Taylor et al. Annals of Clinical and Translational Neurology
- Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis
- (2015) A. E. Elia et al. EUROPEAN JOURNAL OF NEUROLOGY
- Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
- (2015) C.-H. Lu et al. NEUROLOGY
- A phase II−III trial of olesoxime in subjects with amyotrophic lateral sclerosis
- (2014) T. Lenglet et al. EUROPEAN JOURNAL OF NEUROLOGY
- Clinical trials in amyotrophic lateral sclerosis: why so many negative trials and how can trials be improved?
- (2014) Hiroshi Mitsumoto et al. LANCET NEUROLOGY
- Crowdsourced analysis of clinical trial data to predict amyotrophic lateral sclerosis progression
- (2014) Robert Küffner et al. NATURE BIOTECHNOLOGY
- Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients
- (2014) Hazuki Watanabe et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial
- (2013) Merit E Cudkowicz et al. LANCET NEUROLOGY
- Lithium in patients with amyotrophic lateral sclerosis (LiCALS): a phase 3 multicentre, randomised, double-blind, placebo-controlled trial
- (2013) LANCET NEUROLOGY
- Amyotrophic lateral sclerosis disease progression model
- (2013) Roberto Gomeni et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
- (2012) Markus Otto et al. Amyotrophic Lateral Sclerosis
- The effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosis
- (2011) Merit Cudkowicz et al. NATURE MEDICINE
- Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial
- (2010) Swati P Aggarwal et al. LANCET NEUROLOGY
- Prognostic factors in ALS: A critical review
- (2009) Adriano Chiò et al. Amyotrophic Lateral Sclerosis
- Lithium delays progression of amyotrophic lateral sclerosis
- (2008) F. Fornai et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started